Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Resolution of Ibrutinib-Associated Hypertension with Transition to Alternate Covalent Bruton's Tyrosine Kinase Inhibitor

Emily B. Tomasulo, Dylan Therwhanger, Emeline R. Chong, Mitchell E. Hughes, Michael G. Fradley, Stephen J. Schuster

Blood (2024) 144 (Supplement 1): 6802.

https://doi.org/10.1182/blood-2024-211719

Published: 2024

Journal Articles

Pharmacokinetic (PK) Exposure of 4-Hydroxycyclophosphamide Associates with Clinical Benefits of Reduced-Dose Post-Transplantation Cyclophosphamide: Results of a Completed Phase I/II Trial to De-Escalate Post-Transplantation Cyclophosphamide for HLA-Haploidentical Myeloablative Bone Marrow Transplantation

Blood (2024) 144 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2024-212138

Published: 2024

Journal Articles

Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions

Reid M. Muenzen, Emeline R. Chong, Dylan Therwhanger, Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, Mitchell E. Hughes, Elizabeth Weber, Marco Ruella, Noelle V. Frey, David L. Porter, Stephen J. Schuster, Elise A. Chong

Blood (2023) 142 (Supplement 1): 2341.

https://doi.org/10.1182/blood-2023-190434

Published: 2023

Journal Articles

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Blood (2023) 142 (Supplement 1): 308.

https://doi.org/10.1182/blood-2023-183001

Published: 2023

Journal Articles

Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia

Richard B Lock, Kathryn Evans, Ben Watts, Joanna Randall, Cara E Toscan, Eric J Earley, Stephen W Erickson, Brian Belmontes, Philip Wong, Beverly A Teicher, Paul E Hughes, Malcolm A Smith

Blood (2022) 140 (Supplement 1): 11690–11691.

https://doi.org/10.1182/blood-2022-159885

Published: 2022

Journal Articles

Rituximab, Cyclophosphamide, Etoposide and Prednisone for the Treatment of Post-Transplantation Lymphoproliferative Disorder

Reid M. Muenzen, Mitchell E. Hughes, Sunita Dwivedy Nasta, Jakub Svoboda, Daniel J. Landsburg, Stefan K. Barta, Donald Tsai, Stephen J. Schuster, Elise A. Chong

Blood (2022) 140 (Supplement 1): 6715–6716.

https://doi.org/10.1182/blood-2022-169764

Published: 2022

Journal Articles

Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation

Meredith J. McAdams, Mustafa Hyder, Dimana Dimitrova, Jennifer L. Sadler, Christi McKeown, Seth M. Steinberg, Amy Chai, Scott Napier, Anita Stokes, Jennifer Sponaugle, Thomas E. Hughes, Nu Ri Cha, Jennifer Cuellar-Rodriguez, Melissa Walker, Ronald E. Gress, Jennifer A. Kanakry, Christopher G. Kanakry

Blood (2021) 138 (Supplement 1): 101.

https://doi.org/10.1182/blood-2021-146997

Published: 2021

Journal Articles

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors

Jakub Svoboda, Hatcher J Ballard, Carrie I Ho, Mitchell E. Hughes, Elise A Chong, Adam Duca, Sara Prischak, Sunita Dwivedy Nasta, Marco Ruella, Daniel J Landsburg, Stefan K. Barta, James N Gerson, Stephen J. Schuster

Blood (2021) 138 (Supplement 1): 2445.

https://doi.org/10.1182/blood-2021-153122

Published: 2021

Journal Articles

A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-142958

Published: 2020

Journal Articles

Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142299

Published: 2020

Journal Articles

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Jakub Svoboda, MD, Stefan K. Barta, MDMRCP,MS, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Wei-Ting Hwang, PhD, Grace Delp, Brittany Amundsen, Hatcher J. Ballard, BS, James N. Gerson, MD, Elise A. Chong, MD, Mitchell E. Hughes, PharmD, Steven A. Emanuel, Marco Ruella, MD, Stephen J. Schuster, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140507

Published: 2020

Journal Articles

Outcome of Repeated Vaccination to Hepatitis B Virus in Patients Failing to Respond to Vaccination Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): If at First You Don't Succeed, Try Try Again

Reem A Shalabi, PharmD, Michelle A Borg, PharmD, Thomas E Hughes, PharmD, Tracey Walsh-Chocolaad, PharmD, Rodica Ciurea, Lisa Cook, Tatyana Worthy, MSN, Kristen Gunn, Brian Wells, Georg Aue, Xin Tian, Richard W. Childs, MD

Blood (2019) 134 (Supplement_1): 2012.

https://doi.org/10.1182/blood-2019-127336

Published: 2019

Journal Articles

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients

Carrie I Ho, MD, Hatcher J. Ballard, BS, W. Tris Arscott, MD, Mitchell E. Hughes, PharmD, Abigail Doucette, MPH, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, James N. Gerson, MD, Amit Maity, MD PhD, Stephen J. Schuster, MD, Stefan K. Barta, MD MRCP, MS, John Plastaras, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 2905.

https://doi.org/10.1182/blood-2019-124195

Published: 2019

Journal Articles

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Sunita Dwivedy Nasta, MD, Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Daniel J. Landsburg, MD, Elise A. Chong, MD, Stefan K. Barta, MD MRCP, MS, Noelle V. Frey, MD, James N. Gerson, MD, Amit Maity, MD PhD, John Plastaras, MD, David L. Porter, MD, Marco Ruella, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 4108.

https://doi.org/10.1182/blood-2019-131399

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Elise A. Chong, MD, James N. Gerson, MD, Stefan K. Barta, MD MRCP, MS, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5261.

https://doi.org/10.1182/blood-2019-130039

Published: 2019

Journal Articles

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

Sunita Dwivedy Nasta, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Elise A. Chong, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Daniel J. Landsburg, MD, Meredith I LaRose, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Marco Ruella, MD, Noelle V. Frey, MD, Stephen J. Schuster, MD, David L. Porter, MD

Blood (2019) 134 (Supplement_1): 3240.

https://doi.org/10.1182/blood-2019-130650

Published: 2019

Journal Articles

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Elise A. Chong, MD, Meredith I LaRose, MD, Steven M. Bair, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elizabeth Weber, BSN, RN, Chase Walling, BS, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 1606.

https://doi.org/10.1182/blood-2019-131482

Published: 2019

Journal Articles

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Mitchell E. Hughes, PharmD, Tracy M. Krause, PharmD, Colleen Timlin, PharmD, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, David L. Porter, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4023.

https://doi.org/10.1182/blood-2018-99-112604

Published: 2018

NARROW

Resolution of Ibrutinib-Associated Hypertension with Transition to Alternate Covalent Bruton's Tyrosine Kinase Inhibitor

Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia

Rituximab, Cyclophosphamide, Etoposide and Prednisone for the Treatment of Post-Transplantation Lymphoproliferative Disorder

Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors

A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma

Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Outcome of Repeated Vaccination to Hepatitis B Virus in Patients Failing to Respond to Vaccination Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): If at First You Don't Succeed, Try Try Again

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only